Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Sanjay Ram and Jutamas Shaughnessy.
Sanjay Ram
Connection Strength
6.451
Jutamas Shaughnessy
  1. Shaughnessy J, Chabeda A, Lewis LA, Ram S. Alternative pathway amplification and infections. Immunol Rev. 2023 01; 313(1):162-180.
    View in: PubMed
    Score: 0.961
  2. Shaughnessy J, Chabeda A, Tran Y, Zheng B, Nowak N, Steffens C, DeOliveira RB, Gulati S, Lewis LA, Maclean J, Moss JA, Wycoff KL, Ram S. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 2022; 13:975676.
    View in: PubMed
    Score: 0.949
  3. Shaughnessy J, Tran Y, Zheng B, DeOliveira RB, Gulati S, Song WC, Maclean JM, Wycoff KL, Ram S. Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front Immunol. 2020; 11:583305.
    View in: PubMed
    Score: 0.835
  4. Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, DeOliveira RB, Gose S, Reed GW, Botto M, Rice PA, Ram S. Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae. J Immunol. 2018 11 01; 201(9):2700-2709.
    View in: PubMed
    Score: 0.723
  5. Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016 Feb 15; 196(4):1732-40.
    View in: PubMed
    Score: 0.600
  6. Shaughnessy J, Vu DM, Punjabi R, Serra-Pladevall J, DeOliveira RB, Granoff DM, Ram S. Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic. Clin Vaccine Immunol. 2014 Oct; 21(10):1452-9.
    View in: PubMed
    Score: 0.544
  7. Shaughnessy J, Lewis LA, Jarva H, Ram S. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun. 2009 May; 77(5):2094-103.
    View in: PubMed
    Score: 0.373
  8. Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 2019 06; 17(6):e3000323.
    View in: PubMed
    Score: 0.190
  9. Shaughnessy J, Ram S, Rice PA. Biology of the Gonococcus: Disease and Pathogenesis. Methods Mol Biol. 2019; 1997:1-27.
    View in: PubMed
    Score: 0.184
  10. Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis. 2017 06 01; 75(4).
    View in: PubMed
    Score: 0.165
  11. Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology. 2016 10; 221(10):1110-23.
    View in: PubMed
    Score: 0.154
  12. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio. 2013 Oct 15; 4(5):e00339-13.
    View in: PubMed
    Score: 0.128
  13. Shaughnessy J, Ram S, Bhattacharjee A, Pedrosa J, Tran C, Horvath G, Monks B, Visintin A, Jokiranta TS, Rice PA. Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J Biol Chem. 2011 Jun 24; 286(25):22235-42.
    View in: PubMed
    Score: 0.108
  14. Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, M?rgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019 12 05; 4(23).
    View in: PubMed
    Score: 0.049
  15. Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, DeOliveira RB, Shaughnessy J, Reed GW, Ram S, Rice PA. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine. mBio. 2019 11 05; 10(6).
    View in: PubMed
    Score: 0.049
  16. Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol. 2019; 10:321.
    View in: PubMed
    Score: 0.047
  17. Kenno S, Speth C, Rambach G, Binder U, Chatterjee S, Caramalho R, Haas H, Lass-Fl?rl C, Shaughnessy J, Ram S, Gow NAR, Orth-H?ller D, W?rzner R. Candida albicans Factor H Binding Molecule Hgt1p - A Low Glucose-Induced Transmembrane Protein Is Trafficked to the Cell Wall and Impairs Phagocytosis and Killing by Human Neutrophils. Front Microbiol. 2018; 9:3319.
    View in: PubMed
    Score: 0.046
  18. Ermert D, Weckel A, Magda M, M?rgelin M, Shaughnessy J, Rice PA, Bj?rck L, Ram S, Blom AM. Human IgG Increases Virulence of Streptococcus pyogenes through Complement Evasion. J Immunol. 2018 05 15; 200(10):3495-3505.
    View in: PubMed
    Score: 0.044
  19. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico G, Rice PA. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol. 2008 Mar 01; 180(5):3426-35.
    View in: PubMed
    Score: 0.043
  20. Blom AM, Magda M, Kohl L, Shaughnessy J, Lambris JD, Ram S, Ermert D. Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes. J Immunol. 2017 12 01; 199(11):3828-3839.
    View in: PubMed
    Score: 0.042
  21. Wong SM, Shaughnessy J, Ram S, Akerley BJ. Defining the Binding Region in Factor H to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus influenzae. Front Cell Infect Microbiol. 2016; 6:40.
    View in: PubMed
    Score: 0.038
  22. Ermert D, Shaughnessy J, Joeris T, Kaplan J, Pang CJ, Kurt-Jones EA, Rice PA, Ram S, Blom AM. Virulence of Group A Streptococci Is Enhanced by Human Complement Inhibitors. PLoS Pathog. 2015 Jul; 11(7):e1005043.
    View in: PubMed
    Score: 0.036
  23. Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM. Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol. 2014 Nov; 21(11):1505-11.
    View in: PubMed
    Score: 0.034
  24. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 2012; 8(5):e1002688.
    View in: PubMed
    Score: 0.029
  25. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun. 2012 Feb; 80(2):643-50.
    View in: PubMed
    Score: 0.028
  26. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011 Mar 15; 186(6):3606-14.
    View in: PubMed
    Score: 0.027
  27. Beernink PT, Shaughnessy J, Ram S, Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol. 2010 Jul; 17(7):1074-8.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.